Recommendations for the use of meningococcal vaccines in South Africa
Southern African Journal of Infectious Diseases
| Field | Value | |
| Title | Recommendations for the use of meningococcal vaccines in South Africa | |
| Creator | Meiring, Susan Hussey, Gregory Jeena, Prakash Parker, Salim von Gottberg, Anne | |
| Description | Background: Although meningococcal disease (MD) incidence in South Africa is low, Neisseria meningitidis (NM) causes severe disease that is often life-threatening and can cause long-term disabilities. A quadrivalent protein-conjugated meningococcal vaccine (MCV4) is available, and provides protection against 75% of disease causing serogroups in South Africa. Recommendations: We advise vaccination of persons at high risk of meningococcal disease including those with complement deficiency and asplenia; laboratory personnel from reference laboratories who work with NM; and travellers to Saudi Arabia. The need for routine vaccine against meningococcal disease in South Africa is controversial given the current burden of disease. However, due to the high morbidity/mortality of MD we recommend that clinicians consider vaccination of healthy infants and children; HIV-infected persons with a CD4 count 25%; students attending college /university /military academies; and miners.Conclusion: Protein-conjugated meningococcal vaccine is preferable to the polysaccharide vaccine given the ability of the protein-conjugated meningococcal vaccine to induce immune memory, allow for booster responses and eliminate carriage of the organism in the person vaccinated. | |
| Publisher | AOSIS Publishing | |
| Date | 2017-10-01 | |
| Identifier | 10.4102/sajid.v32i3.43 | |
| Source | Southern African Journal of Infectious Diseases; Vol 32, No 3 (2017); 82-86 2313-1810 2312-0053 | |
| Language | eng | |
| Relation |
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:
https://sajid.co.za/index.php/sajid/article/view/43/36
|
|
ADVERTISEMENT
